At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 27 enrolled

Drug / intervention

Gallium Ga 68 DOTA-NeoBOMB1 +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03698370

NCT03698370Phase 2Completed

Compare CT.gov

68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer

Andrei Iagaru·interventional·Posted Oct 9, 2018·Updated Jan 30, 2024

In Brief

A Phase 2 clinical trial evaluating Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 for Prostate Adenocarcinoma and 2 related conditions. Completed, enrolled 27 participants across 1 site.

Detailed Summary

This phase II trial studies how well gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 positron emission tomography (PET)/magnetic resonance imaging (MRI) work in diagnosing participants with prostate cancer that has come back. Diagnostic procedures, such as gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 PET/MRI, may help find and diagnose prostate cancer and find out how far the disease has spread.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsProstate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

20192020202120222023202420252026

First PostedOct 2018

Enrollment StartDec 2020

Primary CompletionFeb 2022

TodayJul 2026

First PostedOct 9, 2018

Enrollment StartDec 15, 2020

Primary CompletionFeb 11, 2022

TodayJul 2, 2026

Enrollment to primary: 1.2 yearsPosted 7.7 years ago

Interventions

Gallium Ga 68 DOTA-NeoBOMB1drug

Administered intravenously (IV)

Gallium Ga 68 PSMA-R2device

Administered intravenously (IV)